Experts Discuss Claudin 18.2: A New Target for Precision Care of Gastric and Gastroesophageal Cancers

In this podcast episode, Samuel Klempner, MD, and Gregory Botta, MD, PhD, provide expert commentary on the rationale and development of novel agents under investigation for targeting claudin 18.2 in gastric and gastroesophageal cancers, with topics including:Expression patterns and function of the claudin family of proteins in normal gastric tissuesBiologic rationale for utility of claudin 18.2 as an actionable therapeutic target in oncologyPrognostic implications of claudin 18.2 overexpression in gastric and gastroesophageal cancersLaboratory methodology involved in claudin 18.2 scoring as a potential predictive biomarker for patient selectionFuture directions for clinical development of agents targeting claudin 18.2, including monoclonal antibodies, bispecific antibodies, antibody‒drug conjugates, and CAR T-cell constructsPresenters:Samuel Klempner, MDAssociate ProfessorDepartment of MedicineDivision of Hematology-OncologyMass General Cancer CenterHarvard Medical SchoolBoston, MassachusettsGregory Botta, MD, PhDClinical Professor of MedicineDepartment of MedicineDivision of Hematology & OncologyUniversity of California San DiegoLa Jolla, CaliforniaContent for this program was supported by educational grants from Astellas and Bristol Myers Squibb.Link to the full program, including a CME-certified text module, downloadable slideset, and ClinicalThought (coming soon!):bit.ly/3lQxPrq